## Supplementary materials:

## Title:

COVID-19 in children in NSW, Australia, during the 2021 Delta outbreak: Severity and Disease spectrum

## **Authors:**

Phoebe Williams\*1,2,3,4, Archana Koirala\*1,2,3, Gemma Saravanos\*1,3, Laura Lopez\*2, Catherine Glover², Ketaki Sharma¹,2, Tracey Williams¹,3, Emma Carey¹,², Nadine Shaw¹, Emma Dickins¹, Neela Sitaram¹, Joanne Ging¹, Paula Bray¹, Nigel Crawford⁵, Brendan McMullan¹,4, Kristine Macartney¹,2,3, Nicholas Wood¹,2,3, Beth Fulton¹, Christine Lau¹, Philip N Britton¹,2,3.

\*Contributed equally

### Affiliations:

- 1. Sydney Children's Hospitals Network;
- 2. National Centre for Immunisation Research and Surveillance;
- 3. Faculty of Medicine and Health, University of Sydney;
- 4. School of Women's and Children's Health, University of New South Wales; NSW, Australia.
- 5. Royal Children's Hospital and Murdoch Children's Research Institute, Melbourne, Victoria, Australia.

# **Correspondance:**

A/Prof Philip Britton
The Children's Hospital at Westmead Clinical School
Locked Bag 4001, Westmead NSW Australia 2145
Email: <a href="mailto:philip.britton@health.nsw.gov.au">philip.britton@health.nsw.gov.au</a>

# **Supplementary Methods:**

Data sources and data use for calculation of rates.

Data Source	Numerator	Denominator	Metric
Paediatric Active	SARS-CoV-2 associated		COVID-19 ICU admission
Enhanced Disease	ICU Admissions at SCHN		'rate'
Surveillance (PAEDS)			
PAEDS	PIMS-TS Admissions at		PIMS-TS admission
	SCHN		'rate'*
NSW Ministry of Health		Statewide age-specific	
		SARS-CoV-2 infection	
PAEDS	SARS-CoV-2 associated		COVID-19 hospital
	'Medical' Admissions at		admission 'rate'
	SCHN		
SCHN 'Home in the	SARS-CoV-2 associated		COVID-19 social
Hospital' program	Social Admissions at		vulnerability 'rate'
(Social admissions)	SCHN		
SCHN VirtualKIDS-CORT		SARS-CoV-2 associated	
		Admissions at SCHN	

Abbreviations: ICU=intensive care unit; NSW=New South Wales, Australia; PIMS-TS= paediatric inflammatory multi-system syndrome temporally associated with SARS-CoV-2; SCHN=Sydney Children's Hospital Network

<sup>\*</sup>PIMS-TS = paediatric inflammatory multi-system syndrome temporally associated with SARS-CoV-2 infection; admission rate calculated using data cut of at 30 September, 2021 given lag time for this 'post-infectious' clinical manifestation.

# **Supplementary Results:**

**Supplementary Table 1:** Case fatality and admission rates overall and by age group and severity of disease amongst cases of SARS-CoV-2 infection managed by SCHN hospitals June - October 2021.

	Rate per 100 infections [95%CI if applicable]						
	0-15 years	0-5 months	6-23 months	2-4 years	5-11 years	12-15 years	
<b>Death</b> (n=1)	0.005	-	-	-	-	0.02	
ICU Admit (n=15)	0.09	0.20	0.06	-	0.05	0.21	
Medical Admit + ICU Admit (n=165)	1.38 [1.17 - 1.59]	12.0 [8.9-15.1]	2.3 [1.5-3.2]	0.9 [0.5-1.3]	0.5 [0.3-0.7]	1.4 [1.0-1.8]	
PIMS-TS* (n=7)	0.04	0.20	0.06	0.09	0.03	-	

<sup>\*</sup>PIMS-TS=paediatric inflammatory multi-system syndrome temporally associated with SARS-CoV-2 infection; admission rate calculated using notification data cut of at 30 September, 2021 given lag time for this 'post-infectious' clinical manifestation.


**Supplementary Table 2.** Full list of clinical features, treatment and outcomes among cases of SARS-CoV-2 infection admitted to SCHN by highest acuity level of care amongst children aged 0-15 years managed through SCHN, June 1 - October 31, 2021.

Characteristic	VirtualKIDS-CORT sample, N = 344 <sup>1</sup>	Medical (non-ICU) admission, N = 150 <sup>1</sup>	ICU admission, N = 15 <sup>1</sup>	<i>P</i> value <sup>2</sup>
Symptomatic	233 / 344 (68%)	150 / 150 (100%)	15 / 15 (100%)	<0.001
Fever	30 / 219 (14%)	99 / 144 (69%)	12 / 15 (80%)	<0.001
Cough	116 / 232 (50%)	108 / 149 (72%)	12 / 15 (80%)	<0.001
Rhinorrhoea	117 / 232 (50%)	90 / 148 (61%)	8 / 15 (53%)	0.14
Ear pain	2 / 230 (0.9%)	1 / 131 (0.8%)	0 / 14 (0%)	>0.9
Oropharyngeal pain	51 / 230 (22%)	14 / 130 (11%)	5 / 14 (36%)	0.005
Dyspnoea	6 / 232 (2.6%)	43 / 146 (29%)	7 / 15 (47%)	<0.001
Wheeze	2 / 232 (0.9%)	6 / 145 (4.1%)	0 / 15 (0%)	0.10
Chest pain	1 / 230 (0.4%)	15 / 130 (12%)	1 / 14 (7.1%)	<0.001
Chest indraw	0 / 232 (0%)	6 / 146 (4.1%)	0 / 15 (0%)	0.005
Myalgia	31 / 230 (13%)	11 / 128 (8.6%)	6 / 14 (43%)	0.004
Arthralgia	12 / 230 (5.2%)	5 / 128 (3.9%)	2 / 14 (14%)	0.2
Fatigue/malaise	66 / 232 (28%)	56 / 143 (39%)	10 / 15 (67%)	0.003
Anosmia	23 / 231 (10.0%)	15 / 129 (12%)	3 / 14 (21%)	0.3
Hypogeusia	29 / 230 (13%)	14 / 129 (11%)	4 / 14 (29%)	0.2
Vomiting/nausea	21 / 232 (9.1%)	52 / 145 (36%)	7 / 15 (47%)	<0.001
Headache	70 / 230 (30%)	32 / 129 (25%)	8 / 14 (57%)	0.042
Diarrhoea	23 / 232 (9.9%)	42 / 147 (29%)	7 / 15 (47%)	<0.001
Confusion/altered	0 / 222 (00/)	4 / 145 (2 00/)	2 / 15 /200/\	<b>40.001</b>
consciousness	0 / 232 (0%)	4 / 145 (2.8%)	3 / 15 (20%)	<0.001
Seizure	0 / 232 (0%)	2 / 145 (1.4%)	1 / 15 (6.7%)	0.020
Abdominal pain	11 / 231 (4.8%)	19 / 132 (14%)	2 / 14 (14%)	0.003
Conjunctivitis	15 / 232 (6.5%)	11 / 145 (7.6%)	0 / 15 (0%)	0.7
Rash	10 / 232 (4.3%)	6 / 145 (4.1%)	3 / 15 (20%)	0.055
Ulcers	1 / 232 (0.4%)	0 / 145 (0%)	0 / 15 (0%)	>0.9
Lymphadenopathy	0 / 232 (0%)	3 / 145 (2.1%)	0 / 15 (0%)	0.11
Bleeding/haemorrhage	0 / 232 (0%)	2 / 145 (1.4%)	1 / 15 (6.7%)	0.020
Other <sup>3</sup>	19 / 232 (8.2%)	77 / 149 (52%)	10 / 15 (67%)	<0.001
Co-pathogen detected	0 / 343 (0%)	9 / 150 (6.0%)	2 / 15 (13%)	<0.001
Medication provided				
Antibiotics	1 / 50 (2.0%)	49 / 116 (42%)	13 / 15 (87%)	<0.001
Antivirals	0 / 50 (0%)	1 / 116 (0.9%)	8 / 15 (53%)	<0.001
Antifungals	0 / 50 (0%)	1 / 115 (0.9%)	2 / 15 (13%)	0.019
Corticosteroids	0 / 50 (0%)	18 / 116 (16%)	14 / 15 (93%)	<0.001
Systemic anticoagulation	NA	6 / 115 (5.2%)	10 / 15 (67%)	<0.001
Respiratory support		404 / 444 / 000/	4 / 45 / 6 30()	<0.001
None	NA	134 / 144 (93%)	1 / 15 (6.7%)	
Low flow oxygen	NA	7 / 144 (4.9%)	2 / 15 (13%)	
High flow oxygen	NA	3 / 144 (2.1%)	2 / 15 (13%)	
Non-invasive ventilation	NA NA	0 / 144 (0%)	3 / 15 (20%)	
Invasive ventilation	NA NA	0 / 144 (0%)	7 / 15 (47%)	0.015
Length of stay (days) Death	NA 0 / 344 (0%)	2 (1, 8)	7 (4, 11) 1 / 15 (6 7%)	0.015
Death	0 / 344 (0%)	0 / 150 (0%)	1 / 15 (6.7%)	0.029

Boldfaced *P* values are significant at an alpha level of 0.05. Abbreviations: ICU, intensive care unit. Numerator and denominator data source is PAEDS. Denominators less than the sample size (N) are due to missing data.


<sup>&</sup>lt;sup>1</sup>n / N (%);<sup>2</sup>Fisher's exact test; Pearson's Chi-squared test; <sup>3H</sup>heterogenous mix of symptoms.

**Supplementary Figure 1.** Proportion of children with symptoms ( $n \ge 10^*$ ) among cases of acute SARS-CoV-2 infection admitted to SCHN by highest acuity level of care amongst children aged 0-15 years managed through SCHN, June 1 - October 31, 2021.



<sup>\*</sup>Excluded from figure: Wheeze (n = 8), Chest indraw (n = 6), Confusion/altered consciousness (n = 7), Seizure (n = 3), Ulcer (n = 1), Lymphadenopathy (n = 3), Haemorrhage (n = 3).

Supplementary Figure 2. Proportion of symptoms by age group ( $n \ge 10^*$ ) among cases of acute SARS-CoV-2 infection (hospitalised (non-ICU and ICU) and VirtualKIDS-CORT) managed through SCHN, June 1 - October 31, 2021.



<sup>\*</sup>Excluded from figure: Wheeze (n = 8), Chest indraw (n = 6), Confusion/altered consciousness (n = 7), Seizure (n = 3), Ulcer (n = 1), Lymphadenopathy (n = 3), Haemorrhage (n = 3).